Agbonlahor Denis Edo, Mirabeau Tatfeng Youtchou, Faith Oviasogie, Inoigbe Omolu Patricia, Samuel Tchouga Kemajou, Clarence Yah Suh
Lahor Research Laboratories, Benin City/College of Health Sciences, Igbinedion University, Okada, Nigeria.
J Microbiol Immunol Infect. 2008 Oct;41(5):393-6.
In areas where malaria is endemic, drug prophylaxis is required for people with sickle cell disease. Chloroquine resistance has been associated with the Plasmodium falciparum multidrug resistance 1 (Pfmdr1) mutant gene. This study tested for the Pfmdr1 86Y mutation in P. falciparum isolates from individuals with sickle cell disease and sickle cell trait, who also underwent hemoglobin genotyping.
Blood samples were collected from patients presenting with symptoms of malaria in an endemic region. The subjects were screened for hemoglobin genotype using hemoglobin electrophoresis and P. falciparum Pfmdr1 genotyping was carried out using polymerase chain reaction-restriction fragment length polymorphism.
229 subjects, comprising 144 with hemoglobin AA genotype, 57 with hemoglobin AS genotype and 28 with hemoglobin SS genotype, were enrolled in this study. There was no significant difference in the infective rate of malaria in the 3 groups (p>0.05). However, the prevalence of Pfmdr1 86Y was higher in those with hemoglobin SS genotype than in hemoglobin AA and AS subjects (p<0.05).
Uncontrolled use of chloroquine is a major cause of chloroquine resistance in Nigeria. Chloroquine prophylaxis may be the underlying cause of the high prevalence of Pfmdr1 86Y mutant gene in individuals with hemoglobin SS genotype.
在疟疾流行地区,镰状细胞病患者需要进行药物预防。氯喹耐药性与恶性疟原虫多药耐药1(Pfmdr1)突变基因有关。本研究检测了镰状细胞病患者和镰状细胞性状个体的恶性疟原虫分离株中的Pfmdr1 86Y突变,这些个体也进行了血红蛋白基因分型。
从疟疾流行地区出现疟疾症状的患者中采集血样。使用血红蛋白电泳对受试者进行血红蛋白基因型筛查,并使用聚合酶链反应-限制性片段长度多态性进行恶性疟原虫Pfmdr1基因分型。
本研究纳入了229名受试者,其中144名血红蛋白基因型为AA,57名血红蛋白基因型为AS,28名血红蛋白基因型为SS。三组疟疾感染率无显著差异(p>0.05)。然而,血红蛋白SS基因型个体中Pfmdr1 86Y的患病率高于血红蛋白AA和AS个体(p<0.05)。
在尼日利亚,氯喹的无节制使用是氯喹耐药性的主要原因。氯喹预防可能是血红蛋白SS基因型个体中Pfmdr1 86Y突变基因高患病率的潜在原因。